Systemic Delivery of Human Growth Hormone by Injection of Genetically Engineered Myoblasts
JYOTSNA DHAwAN,* LYDIA C. PAN,*t GRACE K. PAVLATH, MARILYN A. TRAvIs, ANDREA M. LANCTOT, HELEN M. BLAUt A recombinant gene encoding human growth hormone (hGH) was stably introduced into cultured myoblasts with a retroviral vector. After injection of genetically engineered myoblasts into mouse muscle, hGH could be detected in serum for 3 months. The fate of injected myoblasts was assessed by coinfecting the cells with two retroviral vectors, one encoding hGH and the other encoding f3-galactosidase from Escherichia coli. These results provide evidence that myoblasts, which can fuse into preexisting multinucleated myofibers that are vascularized and innervated, may be advantageous as vehicles for systemic delivery of recombinant proteins.
MAAJOR ADVANCES HAVE BEEN made in the design ofvectors that allow cells to express and secrete recombinant proteins at high concentrations in vitro. Yet, a general problem encountered with a number ofcell types is that expression is not sustained after implantation of genetically engineered cells in vivo (1) (2) (3) . Properties unique to myoblasts appear to enhance the long-term survival and function of these cells after implantation. Myoblasts have the unusual capability of crossing basal lamina (4) . As a result, they contribute progeny to multiple, multinucleated myofibers in the course of normal posmatal mouse development (5) . In addition, myoblasts injected into genetically deficient mdx mice fuse into the muscle fibers of the host and provide a missing endogenous muscle gene product, the intracellular protein dystrophin (6) (7) (8) . Thus tTo whom correspondence should be addressed. 6 DECEMBER 1991 types, become incorporated into a preexisting structure, which is sustained by neuronal activity and in contact with the circulation.
To examine whether myoblasts could deliver nonmuscle gene products to the circulation, we selected hGH for study. Sensitive assays distinguish mouse from human hormones and hGH has a short half-life of 4 min in serum (9) , providing a stringent test for continuous production, secretion, and access to the circulation over time. To introduce the hGH gene into myoblasts, we used the MFG retroviral vector (10) . The efficiency of stably introducing DNA into human myoblasts afforded by this approach is at least three orders of magnitude greater than by stable transfection of plasmids (11) . A second retroviral vector, a-SGC, was used to introduce the E. coli lacZ gene which encodes 3-galactosidase (3-gal) (12) . The average rate of secretion for the entire myoblast pool was 4000 ng per 106 cells per day, on a par with the most effective cell types secreting recombinant hGH in vitro described to date (13) .
Because some retroviral vectors cease to be expressed after cell differentiation or im- Fig. 1 probes were prepared by random priming, blots were washed at high stringenct (0.1 x saline sodium citrate at 65WC), and autoradiograms were exposed for 2 hours ((x actin) or 18 hours (MLC and MyHC). RNA isolation, probes, and random priming were as described (34). To determine whether transduced myoblasts could effectively deliver hGH in vivo, we injected the highest hGH-producing clone (clone 6), which also expressed 13-gal, into the hind limbs of 12 mice. After an initial decline, serum hGH levels plateaued and persisted at approximately 0.5 ng/ml for 35 days (Fig. 2A ). This level was clearly above that of control animals. In a second series of experiments, we injected the entire pool of transduced myoblasts into the hind limbs of 24 mice to determine whether cells that had not been selected by clonal analysis could effectively deliver hGH to the circulation. Again, after an initial decline, hGH levels persisted in serum at 1.0 ng/ml for 30 days (Fig. 2B) . At 85 days, serum hGH levels had risen to 16.1 ng/ml (Fig. 2C) . These results show that hGH encoded by the MFG retrovirus can be continuously produced and secreted by myoblasts implanted into muscle tissue in vivo.
To primarily by implanted cell number. The location of 3-gal-labeled cells was determined at time intervals after implantation by histochemical analysis of serially sectioned hind limbs. During the first few days, multiple small-diameter fibers were observed that are probably derived from implanted myoblasts that had fused to one another. By 10 days, many P-gal-labeled fibers had a large diameter typical of the surrounding tissue, suggesting that implanted cells fused into and contributed to preexisting myofibers (Fig. 3) . Immunohistochemical analysis revealed that these myofibers produced hGH (18) . In general, the morphology of individual fibers and the architecture ofthe tissue as a whole were not greatly altered during the period of stable production of hGH.
Injected myoblasts of the C2C12 cell line appear to have three fates after implantation into mice: some are lost, some become integrated into fibers, and some proliferate. Mice analyzed at late time points, days 56 and 85 after myoblast injection, had elevated serum hGH levels of 5.8 ± 2.6 and 16.1 ± 10.1 ng/ml, respectively, and an abundance of mononucleated myoblast clusters. Proliferation appears to be a characteristic of the permanent C2C12 mouse myogenic cell line that is manifested months after implantation (19) ; it was not observed several months after primary mouse (7, 8) or primary human myoblasts (20) were implanted in mice. (12) ].
tCell number: a standard curve was generated from known numbers of transduced myoblasts (either done 6 for experiments in Fig. 3A , or the entire myoblast pool for experiments in Fig. 3B ) and cell number (mean ± SEM) was estimated from ,B-gal activity (17) Our experiments suggest that myoblasts may have advantages over other cell types (13) (14) (15) (21) (22) (23) (24) as vehicles for long-term delivery of secreted recombinant gene products. There was no evidence of tumor formation after implantation ofprimary human cells (20) .
Myoblast implantation was successful in syngeneic mice (Fig. 2B ) but required continuous immunosuppression in mice mismatched at minor antigens ( Fig. 2A) (25) . Although direct DNA injection circumvents the immune response and has led to remarkable persistence of gene expression in muscle, the efficiency of this method is now too low to be useful for systemic delivery of therapeutic proteins (26) . Thus, strategies for achieving continuous immunosuppression that are less toxic than those that involve cyclosporine A need to be tested (27) and methods for genetically engineering universal donor myoblasts that may evade immune surveillance explored (28) . Fig. 3 . Genetically engineered myoblasts can contribute to existing muscle fibers. Transverse sections of mouse legs 12 days after myoblast implantation show that ,3-gal-labeled myoblasts (top) have fused into large-diameter myofibers (bottom). Lower hind limbs were frozen in melting isopentane, serially sectioned, and fixed and stained for 13-gal activity [as described (12) (30) . From the data presented here, we estimate that approximately 106 pooled myoblasts are capable of producing and secreting 4 ,g of hGH per day in vitro and upon implantation in mice maintain a steady-state serum level of greater than 1 ng/ml (Fig. 2 and Table 1 ). An adult man produces approximately 400 ,ug hGH per day, a production rate that results in a mean serum concentration over 24 hours of 1.8 ng per ml (31) . Thus, in theory, the implantation of approximately 108 myoblasts could provide therapeutic serum levels of hGH in humans. In a phase 1 clinical trial of myoblast transfer in Duchenne muscular dystrophy patients, we have delivered 108 human myoblasts to a small region of a single muscle (32) . In the course of this trial, we have shown that human myoblasts can be purified and expanded to large numbers, as predicted (33) . Taken together, these findings suggest that somatic cell therapy using myoblasts may have application in the delivery to the circulation of a number of recombinant proteins such as hormones, coagulation factors, and anticancer agents for the treatment of inherited and acquired diseases. 
